Are prescription drugs like new cars? Is pharma’s grand bargain a sham? And who keeps your DNA safe?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Nicholas Florko joins us for a discussion of the Trump administration’s efforts to get drug prices into TV ads — and the industry’s vehement opposition. And then we talk about why the best-selling drug in the universe is facing competition overseas but retains a monopoly here in the U.S. Kate Black, 23andMe’s chief privacy officer, talks to us about genetic data security in the age of Facebook (FB) leaks and cold-case surprises. Finally, we run through a big-money cancer deal, what to expect from Europe’s big oncology meeting, and the legacy of the late Microsoft co-founder Paul Allen.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Authors
